Objective
Otitis media (OM) is one of the most frequent diseases in childhood and the most common indication for the prescription of antibiotics. Recurrent OM affects up to 40% of children and may persist for weeks to months causing symptoms ranging from hearing loss and tinnitus to anorexia or conjunctivitis.
The main causative agents of OM are the bacterial pathogens Streptococcus pneumoniae, Moraxella catarrhalis and Haemophilus influenzae. Acute otitis media (AOM) is characterised by the presence of middle ear effusion accompanied by the rapid onset of signs of inflammation such as otalgia, otorrhea or fever. As AOM is very painful, it results very often in antibiotic treatment. Yet solid evidence is lacking that it alters the course of OM disease in children. A prophylactic vaccine would be able to reduce the misery of children by preventing the occurrence of OM altogether. The advances in genomic research have enabled a comprehensive search for antigens and vaccine candidates. Intercell has successfully applied the novel antigenome technology to identify protective antigens from S. pneumoniae. Together with complementary proteomic approaches we now aim to identify novel vaccine candidates for the two pathogens M. catarrhalis and H. influenzae, which can function as targets for protective immunity preventing OM.
This study aims to select candidate antigens for evaluation in clinical trials for the prevention of OM. The consortium partners maintain the highest quality of research and technology in their respective field, among them proven and renowned experts of OM research, proteomic and MS techniques and of vaccine development. This work will generate valuable intellectual property, but it will further broaden the expertise of all partners and the understanding of the underlying mechanisms of OM disease.
Fields of science (EuroSciVoc)
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
- medical and health sciences health sciences infectious diseases RNA viruses influenza
- medical and health sciences basic medicine pharmacology and pharmacy pharmaceutical drugs vaccines
- medical and health sciences basic medicine pharmacology and pharmacy pharmaceutical drugs antibiotics
- medical and health sciences clinical medicine otorhinolaryngology
- medical and health sciences basic medicine pharmacology and pharmacy drug resistance antibiotic resistance
You need to log in or register to use this function
We are sorry... an unexpected error occurred during execution.
You need to be authenticated. Your session might have expired.
Thank you for your feedback. You will soon receive an email to confirm the submission. If you have selected to be notified about the reporting status, you will also be contacted when the reporting status will change.
Programme(s)
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
Topic(s)
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Call for proposal
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
FP6-2005-LIFESCIHEALTH-7
See other projects for this call
Funding Scheme
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
Coordinator
VIENNA
Austria
The total costs incurred by this organisation to participate in the project, including direct and indirect costs. This amount is a subset of the overall project budget.